The company remains in a pre-revenue stage, reporting zero revenue while incurring $1.4 million in R&D expenses during 2026Q1, which underscores the lack of operational leverage.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 6K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -6K | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | -10.54M | -11.63M | 12.57M | 4.68M | 3.86M | 943.93K | 195.86K |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.8M | 4.48M | 6.73M | 928K | 577K | 943.93K | 195.86K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 7.92M | 7.14M | 5.82M | 3.71M | 3.23M | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | -997K | -23.25M | 25K | 45K | 57K | 0 | 0 |
| Operating Income | 10.53M | 11.63M | -12.57M | -4.68M | -3.86M | -943.93K | -195.86K |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 192.53% | -168.55% | -21.27% | -308.93% | -381.94% | - |
| EBITDA | 10.54M | 11.65M | -12.55M | -4.64M | -3.8M | -755K | -195.86K |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | 182.49% | 192.83% | -170.62% | -21.9% | -403.71% | -285.48% | - |
| D&A (Non-Cash Add-back) | 12K | 14K | 25K | 45K | 57K | 0 | 0 |
| EBIT | -12.9M | -11.9M | -16.5M | -5.07M | -3.38M | -755K | -195.86K |
| Net Interest Income | 177K | 129K | -51K | 144K | 29K | 6.37K | 0 |
| Interest Income | 183K | 142K | 1K | 153K | 114K | 6.37K | 0 |
| Interest Expense | 6K | 13K | 52K | 9K | 85K | 0 | 0 |
| Other Income/Expense | -23.44M | -23.54M | -3.94M | -395K | 396K | 188.72K | 0 |
| Pretax Income | -12.91M | -11.91M | -16.51M | -5.08M | -3.46M | -755.22K | -195.86K |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 3K | 3K | 10K | 32K | 24K | 0 | 0 |
| Effective Tax Rate % | -0.02% | -0.03% | -0.06% | -0.63% | -0.69% | 0% | 0% |
| Net Income | -12.91M | -11.91M | -16.44M | -4.94M | -3.21M | -755.22K | -195.86K |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | 23.18% | 27.56% | -232.72% | -53.72% | -325.7% | -285.59% | - |
| Net Income (Continuing) | -12.91M | -11.91M | -16.52M | -5.11M | -3.49M | -755.22K | -195.86K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 3.42M | 3.59M | 0 | 0 |
| EPS (Diluted) | -39.96 | -89.60 | -26.40 | -44.20 | 0.35 | -0.46 | -0.12 |
| EPS Growth % | 403.07% | -239.39% | 40.27% | -12764.76% | 176.2% | -284.87% | - |
| EPS (Basic) | - | -89.60 | -26.40 | -44.20 | 0.35 | -0.46 | -0.12 |
| Diluted Shares Outstanding | 323.04K | 132.95K | 623.85K | 111.73K | 1.67M | 1.65M | 1.65M |
| Basic Shares Outstanding | 323.04K | 132.95K | 623.85K | 111.73K | 1.67M | 1.65M | 1.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by recent financial statements, Silexion Therapeutics maintains a high-intensity cost structure, with R&D expenditures reaching $3.4 million in 2025Q4, which underscores the company's reliance on capital-intensive clinical trial execution to advance its LODER platform toward potential commercialization in the oncology space.
The company's cost profile is dominated by R&D, which fluctuates significantly based on the timing of clinical trial milestones. This volatility in spending suggests that operational discipline is secondary to the immediate necessity of meeting regulatory and clinical development timelines.
Based on reported filings, Silexion Therapeutics recorded $345,000 in stock-based compensation during 2026Q1, a figure that warrants investor scrutiny as it represents a non-cash expense that effectively dilutes existing shareholders while failing to offset the underlying operational losses inherent in the firm's pre-revenue clinical stage.
The reliance on equity-based incentives appears to be a mechanism for talent retention in a competitive biotech hub, yet it obscures the true economic cost of operations. Investors should monitor whether these compensation levels remain sustainable given the company's limited cash runway and lack of commercial revenue.
According to historical income statement data, Silexion Therapeutics exhibits no operating leverage, as the firm consistently reports negative operating income, with quarterly losses reaching $2.7 million in 2026Q1, reflecting a business model that is currently entirely dependent on external financing rather than internal operational efficiency.
The absence of revenue means that any increase in SG&A or R&D spending directly translates into deeper losses. Without a clear path to commercialization, the company lacks the scale required to demonstrate meaningful operating leverage or cost-efficiency improvements.
As reported in financial statements, the company's cash-to-burn ratio suggests a precarious liquidity position, with quarterly losses frequently exceeding $2 million, which implies that the firm may face significant dilution or operational pauses if additional capital is not secured within the next twelve months.
Short-sellers would likely focus on the high probability of a dilutive financing event, which is common for firms at this stage of development. The reliance on specialized interventional procedures for the LODER platform also introduces adoption risks that could further delay the realization of any future revenue.
Quick answers to the most common questions about buying SLXN stock.
For fiscal year 2025, Silexion Therapeutics Ltd. (SLXN) reported total revenue of $0.0M.
Silexion Therapeutics Ltd. (SLXN) reported a net loss of $11.9M for the fiscal year ending 2025.